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Introduction
Breast cancers are highly heterogeneous and include luminal-like tumors expressing the estrogen receptor (ER), HER2-like overexpressing HER2 receptor, and basal-like subtypes that do not express these receptors (triple negative) (1, 2) . While chemotherapy plus hormone therapy (tamoxifen, aromatase inhibitors) or therapies that target HER2 (trastuzumab/Herceptin) significantly reduce the incidence of relapse, most women who develop metastases eventually succumb to the disease. There is, therefore, a great need for novel drugs that can inhibit tumor wide-spectrum, anti-cancer activity of mda-7/IL-24 is not known and may be cancer-specific, depending on pre-existing genetic and epigenetic alterations (3) .
Most strains of rats used experimentally such as Wistar-Furth (WF), develop multiple mammary adenocarcinomas following initiation with a mammary carcinogen, whereas a few strains such as the Copenhagen (Cop) are resistant to the development of mammary tumors (11) .
To investigate these differences in susceptibility, we previously isolated cell lines from tumors induced in resistant Cop x Wistar-Furth F1 rats by infusion of a retrovirus harboring the v-Hasras gene directly into the main mammary ducts (12) . Some of these cell lines grew in soft agar, while others display anchorage-dependent growth. Through microarray analysis, we found that expression of MDA-7/IL-24 and β4 integrin were inversely correlated with the ability to grow in soft agar (13) . Ectopic expression of mda-7/IL-24 in anchorage-independent cells inhibited growth in monolayer culture and in soft agar, their ability to migrate and invade in vitro, and the development of tumors in nude mice. We showed that while β4 integrin did not play a direct role in regulating cell growth, it was a downstream target of MDA-7/IL-24, acting in concert with the latter to suppress cell proliferation. Moreover, we showed that growth suppression by MDA-7/IL-24 was associated with up-regulation of p27 Kip1 via activation of STAT3 (13).
Here we show that mammary tumorigenesis in rats can be blocked by infection with an adenovirus expressing mda-7/IL-24. We demonstrate that growth arrest-specific gene 3 (GAS3/ PMP22), is induced by mda-7/IL-24, and that GAS3 inhibits the attachment and proliferation of tumor cells, at least in part, by blocking the interaction of β1 integrin with fibronectin. Moreover, we show that primary human breast cancers exhibit a positive correlation between expression of the IL-24 receptor and GAS3 and that receptor expression correlates with metastasis free survival. Thus, our data identify a novel inhibitory pathway downstream of mda-7/IL-24, which is important in breast cancer spread and can be targeted for therapy. 
Materials and Methods

Tumor induction
Twenty-four 49 day-old Wistar-Furth female rats were intraperitoneally injected with 75 mg/kg methylnitrosurea (MNU) in 0.05% acetic acid. Thirty days post-injection we infused via the nipples, the main ducts of thoracic, abdominal or inguinal mammary glands of 12 rats (5-7 glands infused/rat) with 15 μl of a solution containing ~ 10 8 pfu of adenovirus containing the human mda-7/IL-24 gene, 8 mg/kg polybrene and 2 g/ml indigo carmine according to our previously published protocol (12) . Glands of 12 control rats were similarly infused with ~ 10 8 pfu of empty adenovirus. The rats were palpated weekly and tumors were harvested when they were >20 mm in diameter or when the animals appeared moribund. A portion of each tumor was fixed in formalin for histological analysis.
Growth of cells in nude mice
Four groups of six female athymic nude mice (CD1 -Nu/Nu), 7 weeks of age, were purchased from Charles River Laboratories (Wilmington, MA, USA). After a week of acclimatization, 2x10 6 FE1.2 cells expressing GAS3 or vector alone, in a volume of 50 μl, were injected subcutaneously. Tumor size was measured twice weekly with vernier calipers by a single-blinded observer. Tumor growth was measured and plotted according to the nonparametric Kaplan-Meier analysis. Tumors were harvested 2 weeks post-injection.
Cell culture
The establishment of the rat breast cancer cell lines was described previously (12) . All cell lines were maintained in α-minimum essential medium (α-MEM), supplemented with 10% fetal bovine serum (FBS), 10 ng/ml epithelial growth factor, 1 μg/ml hydrocortisone and 1μg/ml 17-β-estradiol (Sigma-Aldrich, St Louis, MO). All culture experiments were repeated 3 times.
To examine growth rates, 1x10 7 consecutive days. To examine the regulation of GAS3 by MDA-7/IL-24, FE1.2-IL-24 cells treated with 10 or 20 μM of the STAT3 inhibitor AG9, as previously described (13) .
Attachment assays
Attachment assays were performed on tissue culture plates or on petri dishes pre-coated with fibronectin (20µg/ml) or laminin (20µg/ml). Cells (1x10 4 /ml) were plated in triplicate and counted and photographed 2 or 24 h post-culture. In some experiments, the STAT3 inhibitor AG9 (Calbiochem, Millipore, Ontario) was added to the culture medium of the attached cells and they were photographed 4 h later. The mean percentage of the attached versus the round cells was determined for at least 20 fields of view.
Growth of cells in soft agar
To monitor growth of cells in soft agar, two layers of agarose were used. The bottom layer contained 0.5% agarose, the top layer 0.3% agarose, both in α-MEM. Triplicate samples of 5000 cells were seeded on 6 cm plates and incubated for 5-7 days. At the end of the incubation period, colonies with > 25 cells were counted.
Western blotting
Western blotting was performed either as we have described previously (13) , or for GAS3, as described (32) . Polyclonal rabbit anti-rat antibodies were obtained from the following sources: rabbit anti-rat GAS3 (Abcam, Cambridge, MA) used at a dilution of 1:500; rabbit antirat IL-24 (GenHunter, Nashville, TN) used at a dilution of 1:1000; β-actin (Sigma, St Louis, MO) used at a dilution of 1/50,000; pan-cadherin (Cell Signaling Technology, Danvers, MA) used at a dilution of 1:1000. Protein band densities were determined with the ChemiGenius lysis buffer (1% Nonidet P-40, 2mM phenylmethlsulfonyl, fluoride, 10μg/mL aprotinin, 2μg/mL pepstatin, 10mM iodoacetamide, 0.1mM EDTA, 0.1mM EGTA, 10mM HEPES, and 10mM KCl). Two μg of anti-β1 integrin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was added to 0.5 mg of cell lysates in 1ml and shaken at 4C overnight. Protein-A beads were then added to the mixture and shaking continued for additional 2 h. The beads were then washed 3 times with NP-40 buffer, boiled and proteins separated on 10% SDS-PAGE gel and Western blots prepared using GAS3 and β1 antibodies. To show loading and input controls, Western blots were also prepared from the total extracts (20 µg) using β-actin and GAS3 antibodies.
Immunohistochemistry
Immunohistochemistry was performed on cells grown on cover slips overnight. Cells were fixed in 4% paraformaldehyde (PFA) and blocked using 10% normal goat serum (Jackson ImmnoResearch Laboratories, West Grove, PA). Triplicate cover slips were incubated with 1:500 polyclonal rabbit GAS3 antibody (Novus Biologicals, Littleton, CO) overnight at 4 o C.
Control cells were incubated with buffer only. The next day, the cover slips were incubated with 1:1000 biotinylated goat anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA), for 1 h at room temperature. ABC complex (Vector Laboratories) was then applied to the cover slips for 30 min at room temperature, followed by DAB for 2 min (Vector Laboratories) and counter-staining with Hematoxylin. Cells were dehydrated prior to mounting using xylene base mounting medium.
Infection and transfection
A gas3-producing retrovirus was generated by inserting the entire 658bp coding sequence of rat gas3 in either sense or anti-sense orientations into a unique EcoR1 site in the retroviral expression vector MSCV2.1 (13) . Replication-defective viruses were prepared by transfecting the viral plasmid into the helper-free packaging cell line GP+A (B8) as described previously (13) . For viral infection, supernatants from the virus-producing cells were used to infect FE1.2 cells, plated at a density of 2x10 6 . After 48 h, G418-resistant cells were pooled and subjected to subcloning by limited dilution. Transfection was performed using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen, Carlsbad, CA).
Fibronectin siRNA transfection
Cells were transiently transfected with 2ug of siRNA against fibronectin (Gene Pharma, Shanghai, China) or control oligonucleotides for 6h according to the manufacturer's instructions, as previously described (33) . Fresh medium containing 10% FBS was then added to the transfected cultures and they were maintained overnight, spun down then seeded onto 6-well plates and incubated for 30 min. Attached cells were counted. 
Statistical analysis
Statistical analyses were performed using the two-tailed Student's t-test or ANOVA with significance considered at p<0.05 using Origin 3.5 software (Microcal Software, Northampton, MA). Values are reported as mean ± standard error (SE). The correlation between IL-20R1 and 
Results
Inhibition of rat mammary carcinogenesis by an adenovirus harboring mda-7/IL-24
We have previously shown that mda-7/IL-24 expression blocks the proliferation of rat mammary tumor cells in vitro (13) Table I ). Histological analysis showed that all tumors were typical adenocarcinomas (12) . In contrast, during the same time period, no mammary tumors developed in the glands of rats infused with the mda-7/IL-24-containing adenovirus (significantly different from controls, p<0.005 by χ 2 analysis). Interestingly, two tumors developed in these rats in glands that had not been infused with adenovirus-mda-7/IL-24. These results demonstrate that mda-7/IL-24 expression inhibits breast cancer development in vivo.
mda-7/IL-24 induces GAS3 expression
We previously showed that proliferation and anchorage-independent growth of FE1.2 tumor cells were readily suppressed by MDA-7/IL-24 (12) . To begin to address the mechanism of this growth inhibition, four independent RNA isolates of FE1. Table II ). Of particular interest was the 27.8-fold up-regulation of gas3, a gene initially identified in quiescent, serum-starved NIH-3T3 mouse fibroblasts (15). We also observed a 10.2-fold increase in expression of β4 integrin, which we previously showed to be upregulated by mda-7/IL-24 (13) . We confirmed MDA-7/IL-24-induced expression of gas3 in FE1.2 cells by quantitative real-time PCR (Fig. 1A) and immunoblotting (Fig. 1B) . Furthermore, we demonstrated that the levels of gas3 RNA and protein were significantly higher in anchorage-dependent FE1.3 cells, which expressed high levels of mda-7/IL-24 (13) , than in FE1.2 cells, which express negligible amounts of this cytokine (Fig. 1) . Thus, these studies identify GAS3 as a target of mda-7/IL-24 both at the RNA and protein levels in mammary tumor cells.
GAS3 expression suppresses the growth of rat mammary tumor cells in monolayer culture and in soft agar
We first showed that growth arrest induced by serum starvation induced GAS3 expression in both FE1.2 (28-fold) and FE1.3 (10-fold) cells (Supplemental Fig. 1 ). To determine directly the effect of gas3 expression on FE1.2 cell growth, we infected these cells with a retrovirus (MSCV2.1) expressing gas3 (FE1.2+GAS3) or vector control (FE1.2+Vector).
Western blot analysis confirmed high expression of GAS3 only in FE1.2+GAS3 cells (Fig. 2A) .
When cultured in vitro, FE1.2+GAS3 cells displayed a reduced ability to proliferate in adherent, monolayer cultures compared to FE1.2+Vector cells (Fig. 2B ). GAS3 expression also significantly suppressed the number of colonies that grew in soft agar compared to control cells (Fig. 2D ).
To test for dependency of mda-7/IL-24-induced suppression of cell proliferation on gas3, we knocked-down gas3 expression by siRNA in FE1.2+IL-24S cells which overexpress GAS3 (Supplemental Fig. 2A ). Stable expression of gas3 siRNA led to a 50% knockdown of GAS3 expression (Supplemental Fig. 2A/B ). This partial knockdown of GAS3 resulted in a significant increase in the number of colonies formed in soft agar compared to parental cells (Supplemental Fig. 2C ).
To identify the mechanism by which MDA-7/IL-24 induces GAS3, we treated FE1-2+IL-24 cells with an inhibitor of STAT3, which we previously showed to mediate growth inhibition by MDA-7/IL-24 through up-regulation of p27 Kip1 (13) . The FE1.2+IL-24 cells treated with 10 or 20 μM of the STAT3 inhibitor AG9 exhibited a 43% and 59% reduction, respectively, in GAS3 expression (Fig. 2E) . Addition of AG9 to the culture of the GAS3 over-expressing FE1.2+GAS3 cells also significantly inhibited attachment to the plates (Supplemental Figures   3A and B) . Thus, MDA-7/IL-24 induces GAS3 and promotes attachment through a STAT3-dependent pathway. Together, these results define GAS3 as a critical mediator of mda-7/IL-24-induced growth suppression of rat mammary tumor cells and indicate that GAS3 expression alone suffices to inhibit cell proliferation both in vitro and in vivo.
GAS3 growth inhibition is mediated through its binding to β1 integrin and disruption of interaction with the β1 ligand fibronectin
Next, we sought to determine the downstream target of the MDA-7/IL-24/GAS3 pathway. We noticed that under normal growth conditions, FE1.2+vector control cells displayed (Fig. 3) and remained alive after becoming fully confluent. In contrast, FE1.2+GAS3 cells proliferated slowly (Fig. 2B) , displayed rounded morphology (Fig. 3) and rapidly died when they reached semi-confluent growth (Supplemental Fig. 4) , suggesting that GAS3 expression may alter cell attachment. Indeed, GAS3 directly binds β1 integrin as revealed by immunoprecipitation (Supplemental Fig. 5 ). The interaction was specific to β1 integrin since we observed no binding of GAS3 to β4 integrin (data not shown), even though we previously demonstrated induction of β4 integrin by MDA-7/IL-24 (13) . Our observation of GAS3-β1 integrin interaction is consistent with a previous report suggesting that GAS3 might affect cellcell interaction through this integrin (16) .
To examine whether GAS3 expression alters cellular attachment, FE1.2+GAS3 or control cells were seeded at the same density onto Petri dishes coated with fibronectin, the ligand for β1 integrin (17) . In control uncoated dishes, minimal attachment was observed by either FE1.2+GAS3 or control cells (Fig. 3) . Fibronectin coating resulted in a dramatic increase in cell attachment for FE1.2+vector cells (86% ± 4) compared to FE1.2+GAS3 cells (56% ± 4) two hours after plating (Supplemental Fig. 6A ). Due to the shorter doubling time of control cells, there was a further increase in their number compared to the FE1.2+GAS3 cells 24 hours postplating (Supplemental Fig. 6B ). FE1.2 cells expressing a glycosylated mutant of GAS3 (designated GAS3GM and described in more detail below) had attachment and proliferation levels similar to FE1.2+Vector cells (Supplemental Fig. 6A and B) . In contrast to the differential growth on fibronectin-coated plates, FE1.2+GAS3 cells attached as well or even better than control cells to plates coated with laminin, the ligand for the β4 integrin ( Fig. 3 ; Supplemental 
endogenous fibronectin expression in FE1.2+GAS3 cells compared to FE1.2+vector cells (Fig.   4A) . However, the level of fibronectin released into the medium by GAS3 overexpressing cells was much lower than control cells (Fig. 4B) , suggesting that GAS3 interaction with β1 integrin inhibits secretion of fibronectin, resulting in intracellular accumulation of this factor. To test the effect of controlled fibronectin downregulation on the growth of FE1.2 cells, we knocked down fibronectin expression using three independent siRNA treatments (Fig. 4C) . These siRNAs significantly inhibited attachment of cells overexpressing GAS3 as well as control cells in proportion to the knockdown efficiency of fibronectin expression (Fig. 4D) . Our results suggest that GAS3 inhibits cell attachment through two complementary mechanisms: reduction in endogenous fibronectin secretion and reduction in β1 integrin interaction with exogenous fibronectin.
Mutation within an N-linked glycosylated site of GAS3 restores fibronectin-mediated attachment and growth retardation in culture
The GAS3 protein has been previously reported to contain three consensus motifs for Nlinked glycosylation (18) . To determine the role of GAS3 glycosylation on cell growth inhibitory activity and the interaction of fibronectin with β1 integrin, we generated a GAS3 mutant allele carrying NCT to EEE substitutions at amino acid positions 41-43 (GAS3GM). This allele was cloned into a retroviral vector and transduced into FE1. (Fig. 6A-C and Supplemental Fig. 6A ). Consistent with these results, we showed that glycosylation defective GAS3 failed to bind β1 integrin (Fig. 5A) . These results suggest that glycosylation of GAS3 is critical for its binding to β1 integrin and its ability to inhibit attachment to fibronectin, tumor cell growth and survival.
Expression of mda-7/IL-24 receptor IL-20R1 correlates with GAS3 expression and predicts clinical outcome of breast cancer patients
To extend our studies to human cancer, we first tested the effect of mda-7/IL-24 on GAS3 expression and growth of the human breast cancer cell line MD-MBA-231 and MD-
MBA-435 (19). After transducing these cells with the retroviral vector encoding mda-7/IL-24,
GAS3 expression was strongly induced (Fig. 7A, left) . Furthermore, growth of both cell lines was significantly reduced (Fig. 7A, right) , in agreement with other reports using human melanoma cells (4, 5, 20) and our results with rat mammary tumor cells (Fig. 2) . ( Fig. 7C, left) . Since Ha-ras is activated in MNU-induced rat mammary tumors (21, 22), we asked whether the risk of metastasis further increased in the low IL-20R1 subgroup in HER2 + breast cancers in which ras is activated. Indeed, patients with 2-fold higher HER2 expression and low IL-20R1 expression had a significantly worse prognosis, with an HR of 2.22, compared to those with low HER2 and high IL-20R1 expression (p=0.0485) (Fig. 7C, right) . Thus, expression of the mda-7/IL-24 receptor correlates with GAS3 expression and reduced incidence of metastasis.
Discussion
Cancer development is a multistep process associated with the accumulation of mutations in various oncogenes and tumor suppressor genes. In addition to these genetic events, epigenetic and microenvironmental factors contribute significantly to this process (23) . Resistance to cancer development has been reported for a number of different tissues in rats and is linked to distinct loci (11) . We previously showed that mda-7/IL-24 suppresses the growth of rat mammary carcinoma cells and may play a role in the resistance of some strains of rats to mammary carcinogenesis (13) . In the present study, we provide direct in vivo evidence to support 
To understand how mda-7/IL-24 signaling inhibits the growth of breast cancer, we performed a microarray analysis of genes induced when mda-7/IL-24 was over-expressed in our anchorage-independent rat mammary cell line FE1.2. We showed that mda-7/IL-24 expression led to an almost 30-fold upregulation of the gas3 gene. We confirmed this induction at the protein level and showed that it was STAT3-dependent. GAS3 was originally shown to be associated with growth arrest in serum-starved NIH-3T3 fibroblasts (15). Gas3 expression is driven by two alternate promoters P1 and P2, which drive transcription of two transcripts 1A and 1B respectively, containing different non-coding exons (25) . Both transcripts yield identical proteins, but the two promoters confer tissue-specific control of expression (26) . P1 leads to expression in the peripheral and central nervous systems and is thought to be important for myelin formation (27, 28) . Amplification of the gas3/PMP22 locus is associated with the autosomal dominant Charcot-Marie-Tooth disease (29) . Our results suggest it is important to test whether GAS3 and the downstream pathway described here are also involved in this progressive neuropathic syndrome.
We demonstrated that over-expression of GAS3 in rat mammary cancer cells that normally express negligible amounts of this protein, inhibits their proliferation in culture and growth in nude mice. Thus, we have demonstrated for the first time that the inhibition of cancer cell growth by mda-7/IL-24 is mediated, at least in part, through up-regulation of GAS3.
Consistent with a previous study (16) , we have shown that GAS3 binds to β1 integrin, and demonstrated that this interaction depends on N-glycosylation of GAS3. Moreover, we showed that this binding blocks the interaction of β1 integrin with its ligand fibronectin. We also demonstrated that siRNA-mediated down-regulation of fibronectin reduced survival of breast cancer cells, suggesting that binding of GAS3 to β1 integrin plays a critical role in its ability to inhibit cancer cell growth. Our results are consistent with previous observations in which 
peptides containing the integrin recognition sequence RGD, can inhibit metastasis of mouse melanoma cells by blocking α4-β1 interaction (18) and that the tumor-suppressive activity of mda-7/IL-24 can be significantly increased when the RGD sequence is fused in frame with the mda-7/IL-24 gene (30) . Surprisingly, we showed that mammary cancer cells expressing a glycosylation mutant form of GAS3 bind better to fibronectin coated plates and exhibit a higher growth rate in soft agar than cells expressing native GAS3. This additional growth potential may stem from the ability of mutant GAS3 to compete out inhibitory effects of the remaining wild-type GAS3. 
